{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:06:21Z","timestamp":1781114781932,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002461","name":"Chungbuk National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13300-024-01604-8","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T08:01:31Z","timestamp":1716278491000},"page":"1615-1626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Efficacy and Safety of Sodium-Glucose Co-transporter\u00a02 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type\u00a02 Diabetes (T2D)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1552-3205","authenticated-orcid":false,"given":"Dong-Hwa","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jeong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-9671","authenticated-orcid":false,"given":"Tae Keun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"22","key":"1604_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"4","key":"1604_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"9733","key":"1604_CR3","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type\u00a02 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(10)60407-2.","journal-title":"Lancet"},{"issue":"2","key":"1604_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"S\u00f8fteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type\u00a02 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201\u20139. https:\/\/doi.org\/10.2337\/dc16-1347.","journal-title":"Diabetes Care"},{"key":"1604_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01323-5","volume":"20","author":"J Real","year":"2021","unstructured":"Real J, Vlacho B, Ortega E, et al. Cardiovascular and mortality benefits of sodium\u2013glucose co-transporter-2 inhibitors in patients with type\u00a02 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol. 2021;20:1\u201311. https:\/\/doi.org\/10.1186\/s12933-021-01323-5.","journal-title":"Cardiovasc Diabetol"},{"key":"1604_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0737-5","volume":"17","author":"YG Kim","year":"2018","unstructured":"Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium glucose co-transporter\u00a02 inhibitors and a reduced risk of heart failure in patients with type\u00a02 diabetes mellitus: a real-world nationwide population-based cohort study. Cardiovasc Diabetol. 2018;17:1\u20139. https:\/\/doi.org\/10.1186\/s12933-018-0737-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"1604_CR7","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111\u201324. https:\/\/doi.org\/10.2337\/dc21-S009.","journal-title":"Diabetes Care"},{"key":"1604_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomized controlled trials and population-based observational research; partners in the evolution of medical evidence. BJC. 2014;110:551\u20135. https:\/\/doi.org\/10.1016\/bjc.2013.725.","journal-title":"BJC"},{"key":"1604_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMra1614394","volume":"377","author":"TR Frieden","year":"2020","unstructured":"Frieden TR. Evidence for health decision making\u2014beyond randomized controlled trials. N Engl J Med. 2020;377:465\u201375. https:\/\/doi.org\/10.1056\/NEJMra1614394.","journal-title":"N Engl J Med"},{"issue":"6","key":"1604_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JPH Wilding","year":"2012","unstructured":"Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type\u00a02 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405\u201315. https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00003.","journal-title":"Ann Intern Med"},{"key":"1604_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13098-017-0297-y","volume":"9","author":"Y Thewjitcharoen","year":"2017","unstructured":"Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr. 2017;9:96. https:\/\/doi.org\/10.1186\/s13098-017-0297-y.","journal-title":"Diabetol Metab Syndr"},{"key":"1604_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","volume":"151","author":"EJ Ku","year":"2019","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type\u00a02 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65\u201373. https:\/\/doi.org\/10.1016\/j.diabres.2019.04.008.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1604_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/dom.13476","volume":"21","author":"EJ Ku","year":"2019","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type\u00a02 diabetes: an observational study in clinical practice. Diabetes Obes Metab. 2019;21(1):173\u20137. https:\/\/doi.org\/10.1111\/dom.13476.","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"1604_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"1604_CR15","unstructured":"ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med. 2001;47(2):121\u2013130."},{"issue":"12","key":"1604_CR16","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type\u00a02 diabetes. Diabetes Care. 2013;36(12):4015\u201321. https:\/\/doi.org\/10.2337\/dc13-0663.","journal-title":"Diabetes Care"},{"key":"1604_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12459","volume":"6","author":"S Del Prato","year":"2015","unstructured":"Del Prato S, Nauck M, Dur\u00e1n-Garcia S, et al. Long-term\u00a0glycaemic response and tolerability of\u00a0dapagliflozin\u00a0versus a sulphonylurea as add-on therapy to metformin in patients with\u00a0type\u00a02\u00a0diabetes: 4-year data. Diabetes Obes Metab. 2015;6:581\u201390. https:\/\/doi.org\/10.1111\/dom.12459.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1604_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.12327","volume":"16","author":"MA Nauck","year":"2014","unstructured":"Nauck MA, Del Prato S, Dur\u00e1n-Garc\u00eda S, et al. Durability of glycaemic\u00a0efficacy\u00a0over\u00a02\u00a0years with\u00a0dapagliflozin\u00a0versus glipizide as add-on therapies in patients whose\u00a0type\u00a02\u00a0diabetes\u00a0mellitus\u00a0is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111\u201320. https:\/\/doi.org\/10.1111\/dom.12327.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"1604_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"23","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type\u00a02 diabetes: a double-blind extension of a phase\u00a0III randomized controlled trial. Cardiovasc Diabetol. 2015;23(14):154. https:\/\/doi.org\/10.1186\/s12933-015-0314-0.","journal-title":"Cardiovasc Diabetol"},{"key":"1604_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon IO, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care. 2020;43:468\u201375. https:\/\/doi.org\/10.2337\/dc19-1476.","journal-title":"Diabetes Care"},{"issue":"2","key":"1604_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdi.13125","volume":"11","author":"K Kaku","year":"2020","unstructured":"Kaku K, Naito Y, Senda M, et al. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type\u00a02 diabetes mellitus: a subanalysis of a post-marketing study (J-STEP\/EL Study). J Diabetes Investig. 2020;11(2):405\u201316. https:\/\/doi.org\/10.1111\/jdi.13125.","journal-title":"J Diabetes Investig"},{"key":"1604_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2231","volume":"353","author":"F Salvo","year":"2016","unstructured":"Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231. https:\/\/doi.org\/10.1136\/bmj.i2231.","journal-title":"BMJ"},{"key":"1604_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/jch.14131","volume":"23","author":"K Okada","year":"2021","unstructured":"Okada K, Hoshide S, Kato M, Kanegae H, Ishibashi S, Kazuomi K. Safety and efficacy of empagliflozin in elderly Japanese patients with type\u00a02 diabetes mellitus: a post hoc analysis of data from the SACRA study. J Clin Hypertens. 2021;23:860\u20139. https:\/\/doi.org\/10.1111\/jch.14131.","journal-title":"J Clin Hypertens"},{"issue":"2","key":"1604_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jdi.13333","volume":"12","author":"K Utsunomiya","year":"2021","unstructured":"Utsunomiya K, Koshida R, Kakiuchi S, et al. Safety and effectiveness of tofogliflozin in Japanese patients with type\u00a02 diabetes mellitus treated in real-world clinical practice: results of a 36-month post-marketing surveillance study (J-STEP\/LT). J Diabetes Investig. 2021;12(2):184\u201399. https:\/\/doi.org\/10.1111\/jdi.13333.","journal-title":"J Diabetes Investig"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01604-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:34:46Z","timestamp":1719484486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01604-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1604"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01604-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dong-Hwa Lee, Ji Hwan Oh, Hyun Jeong Jeon and Tae Keun Oh have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was carried out in accordance with the principles stated in the Declaration of Helsinki, as revised in 2013 and the International Conference of Harmonization\/Good Clinical Practice guidelines. An institutional review board at Chungbuk National University Hospital approved the study (No. 2024-01-010-001), and the written consent from patients to participate was waved because this study was performed retrospectively.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}